Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
$37.75
-1.3%
$40.25
$26.20
$63.50
$1.76B1.441.17 million shs647,369 shs
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$14.29
-2.0%
$14.18
$7.86
$17.75
$1.74B1.841.46 million shs1.67 million shs
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$7.67
-1.3%
$8.10
$6.85
$19.89
$458.54M-0.08295,720 shs259,804 shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$31.98
+5.7%
$28.38
$17.82
$32.15
$2.21B0.14611,693 shs1.07 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-1.33%-7.52%-14.82%-5.91%-22.48%
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-1.99%-3.84%+3.85%-6.23%+41.91%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-1.29%-6.23%-1.16%-12.74%-60.36%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
+5.68%+21.46%+16.55%+15.66%+20.23%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
2.4768 of 5 stars
3.50.00.00.03.44.20.0
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.7155 of 5 stars
3.43.00.00.02.81.70.6
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
1.5964 of 5 stars
3.51.00.00.00.61.70.6
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
3.1499 of 5 stars
3.53.00.00.02.53.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
3.00
Buy$99.00162.25% Upside
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.83
Moderate Buy$19.4035.76% Upside
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3.00
Buy$30.00291.13% Upside
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
3.00
Buy$41.1728.73% Upside

Current Analyst Ratings Breakdown

Latest CGEM, KNSA, APGE, and ARQT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$45.00 ➝ $54.00
7/25/2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$18.00
7/21/2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$36.00
7/9/2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $42.00
7/7/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/7/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$90.00
7/7/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $115.00
7/2/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$116.00
6/11/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$22.00
5/23/2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
5/12/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $24.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/A$15.92 per shareN/A
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$196.54M8.67N/AN/A$1.35 per share10.59
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/A$10.14 per shareN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$423.24M5.51N/AN/A$6.78 per share4.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$182.15M-$3.60N/AN/AN/AN/A-28.35%-26.98%8/11/2025 (Estimated)
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$140.04M-$1.04N/AN/AN/A-60.95%-80.66%-32.94%8/6/2025 (Estimated)
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$167.38M-$2.91N/AN/AN/AN/A-29.47%-28.19%8/6/2025 (Estimated)
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
-$43.19M$0.04799.70127.92N/A0.90%1.05%0.80%N/A

Latest CGEM, KNSA, APGE, and ARQT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$0.7951N/AN/AN/AN/AN/A
8/11/2025Q2 2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$1.08N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$0.19N/AN/AN/A$72.70 millionN/A
7/29/2025Q2 2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.18$0.23+$0.05$0.23$145.21 million$156.80 million
5/12/2025Q1 2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$1.19-$0.95+$0.24-$0.95N/AN/A
5/8/2025Q1 2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$0.78-$0.74+$0.04-$0.74N/AN/A
5/6/2025Q1 2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/AN/A
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/AN/AN/AN/AN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/A
15.82
15.82
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
0.75
3.55
3.37
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/A
11.62
11.62
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/A
3.57
3.43
CompanyEmployeesShares OutstandingFree FloatOptionable
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
9146.05 million26.35 millionOptionable
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
150119.20 million108.00 millionOptionable
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3059.01 million54.79 millionOptionable
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
22072.97 million33.95 millionOptionable

Recent News About These Companies

Wedbush Research Analysts Lift Earnings Estimates for KNSA
Earnings Preview: Kiniksa Pharmaceuticals

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apogee Therapeutics stock logo

Apogee Therapeutics NASDAQ:APGE

$37.75 -0.51 (-1.33%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$37.73 -0.02 (-0.05%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Arcutis Biotherapeutics stock logo

Arcutis Biotherapeutics NASDAQ:ARQT

$14.29 -0.29 (-1.99%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$14.39 +0.10 (+0.67%)
As of 08/1/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Cullinan Therapeutics stock logo

Cullinan Therapeutics NASDAQ:CGEM

$7.67 -0.10 (-1.29%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$7.68 +0.00 (+0.07%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Kiniksa Pharmaceuticals International stock logo

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$31.98 +1.72 (+5.68%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$32.79 +0.81 (+2.54%)
As of 08/1/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.